Obesity Featured Articles

  1. 5 Sponsor Contracting Issues That Delay Clinical Trials — And How To Avoid Them 10/7/2026

    CTA negotiations don’t have to stall study start-up. Learn five sponsor-side contracting issues that cause delays and practical ways to prevent them.

  2. Participant Payment — Make It Make Cents 10/6/2026

    Participant payment practices and expectations vary wildly. With advocate T.J. Sharpe, explore why sponsors need to rethink how they appreciate participants' time, effort, and burden.

  3. The Cost Of Caution In Clinical Trial Participant Support 10/5/2026

    Regulatory uncertainty around participant payments can create practical barriers to participation. Explore how clearer protections can support appropriate reimbursement while preserving safeguards.

  4. Where Clinical Trial Reimbursement Gets Complicated 10/5/2026

    Learn where participant reimbursement can break down in clinical trials and how clearer payment processes can reduce delays and unnecessary work for research sites.

  5. What Ecological Momentary Assessment Taught Us About Real-World Hearing Outcomes 10/5/2026

    Ecological momentary assessment (EMA) reveals how people experience hearing challenges beyond the clinic. Here, researchers highlight its relevance in designing real-world hearing studies.

  6. Harness An Adept IRB's Expertise To Streamline Study Design 10/2/2026

    An Institutional Review Board protects human research participants by evaluating study ethics, consent, and risks, while providing sponsors with ongoing guidance on complex trial protocols.

  7. Calidi's Study Aims To Have An Oncolytic Virus Outsmart The Immune System 10/2/2026

    Calidi’s Eric Poma, Ph.D., explains how CLD-401 could evade immune clearance — and how the biotech is designing Phase 1 to prove safety and efficacy fast.

  8. Early-Phase Lab Data: Why It Breaks And How To Prevent Risk 10/1/2026

    Learn why lab data systems built quickly in early-phase trials tend to outlast their usefulness, quietly accumulating inconsistencies that surface only when scrutiny intensifies later in a study.

  9. With CROs, Decide What You Can Actually Manage 10/1/2026

    Industry veteran Peter Fredette explores how small biotechs can rethink CRO outsourcing by balancing cost, operational needs, and internal oversight. Before choosing a CRO model, sponsors must honestly assess which services they need — and how many partners they can realistically manage.

  10. New Imaging Approach Could Improve IPF Trial Design 10/1/2026

    AI-powered quantitative CT could help sponsors detect treatment effects earlier, strengthen IPF trial endpoints, and make better go/no-go decisions.